Recurrent Gastric Cancer

Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (01-23-2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum,... Continue Reading

IMAB362 Leads to Longer Remission and Better Survival in Gastric Cancer (06-6-2016)

The results of a novel treatment for gastric cancer with the investigational antibody IMAB362 were released at the American Society of Clinical Oncology (ASCO) this week. IMAB362 led to extended remissions and prolonged survival for patients with advanced... Continue Reading

Afinitor® Promising in Neuroendocrine Tumors Originating in Gastrointestinal Tract or Lungs (08-10-2015)

The drug Afinitor® (everolimus) is currently be studied in a Phase III clinical trial for patients with nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract or lungs. The trial is ongoing, but findings so far are promising: patients... Continue Reading

U.S. FDA Issues Warning about Certain Type of Endoscope (02-20-2015)

The U.S. Food and Drug Administration (FDA) has issued a Safety Communication about a certain type of endoscope­—specifically the device used in endoscopic retrograde cholangiopancreatography (ERCP). According to the FDA, the device may be difficult... Continue Reading

AMG 337 MET Inhibitor Produces Impressive, Rapid Response in Gastric and Esophageal Cancers (02-12-2015)

AMG 337 is a novel small-molecule MET inhibitor that appears to show promise in the treatment of MET-amplified gastroesophageal junction, gastric, and esophageal cancers. MET inhibitors are a class of small molecules that inhibit the enzymatic activity... Continue Reading

FDA Approves Cyramza™ in Combination With Paclitaxel for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (11-13-2014)

(CancerConnect) The U.S. Food and Drug Administration(FDA) has approved Cyramza™ (ramucirumab) for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma. Cyramza was approved... Continue Reading

Apatinib Prolongs Survival in Advanced Gastric Cancer (06-26-2014)

Apatinib significantly improved overall survival according to the results of a phase III study presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Gastric cancer refers to cancer of the stomach. Though gastric... Continue Reading

Ramucirumab Plus Paclitaxel Improves Survival in Metastatic Gastric Cancer (02-21-2014)

Ramucirumab significantly improved both progression-free and overall survival, when added to paclitaxel in second-line therapy for metastatic gastric cancer, according to the results of a study presented at the 2014 Gastrointestinal Cancers Symposium. Gastric... Continue Reading

Second-Line Docetaxel Improves Survival in Esophageal and Gastric Cancer (04-3-2013)

Second-line treatment with docetaxel improves overall survival of patients with advanced esophageal and gastric cancer, according to the results of a study presented at the 2013 Gastrointestinal Cancers Symposium in San Francisco. The esophagus is a muscular... Continue Reading

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (11-16-2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival or duration of functional independence but does... Continue Reading

Next Page »